Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 13, 2013, Pages 5145-5150

  Labrijn, Aran F ^a   Meesters, Joyce I ^a   De Goeij, Bart E C G ^a   Van Den Bremer, Ewald T J ^a   Neijssen, Joost ^a   Van Kampen, Muriel D ^a   Strumane, Kristin ^a   Verploegen, Sandra ^a   Kundu, Amitava ^b   Gramer, Michael J ^b   Van Berkel, Patrick H C ^a   Van De Winkel, Jan G J ^a,c   Schuurman, Janine ^a   Parren, Paul W H I ^a  

^a GENMAB   (Netherlands)

^b Genmab   (United States)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Anti tumor; Immunotherapy; Pharmacokinetics

Indexed keywords

BISPECIFIC ANTIBODY; IMMUNOGLOBULIN G1;

ARTICLE; CONTROLLED FAB ARM EXCHANGE; DRUG MANUFACTURE; DRUG TARGETING; HUMAN; HUMAN CELL; IMMUNOGLOBULIN STRUCTURE; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; PROCEDURES, PARAMETERS AND DEVICES; PROTEIN EXPRESSION; TECHNOLOGY;

ANIMALS; ANTIBODIES, BISPECIFIC; CHO CELLS; CRICETINAE; CRICETULUS; HEK293 CELLS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; JURKAT CELLS; RECOMBINANT PROTEINS;

EID: 84875542050     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1220145110     Document Type: Article

References (43)

1. Chan AC, Carter PJ (2010) Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 10(5):301-316.
2. Carter P (2001) Bispecific human IgG by design. J Immunol Methods 248(1-2):7-15.
3. Chames P, Baty D (2009) Bispecific antibodies for cancer therapy. Curr Opin Drug Discov Devel 12(2):276-283.
4. Kufer P, Lutterbüse R, Baeuerle PA (2004) A revival of bispecific antibodies. Trends Biotechnol 22(5):238-244.
5. Jackman J, et al. (2010) Development of a two-part strategy to identify a therapeutic human bispecific antibody that inhibits IgE receptor signaling. J Biol Chem 285(27): 20850-20859.
6. Milstein C, Cuello AC (1983) Hybrid hybridomas and their use in immunohistochemistry. Nature 305(5934):537-540.
7. Merchant AM, et al. (1998) An efficient route to human bispecific IgG. Nat Biotechnol 16(7):677-681.
8. Lindhofer H, Mocikat R, Steipe B, Thierfelder S (1995) Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. J Immunol 155(1):219-225.
9. Schaefer W, et al. (2011) Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci USA 108(27): 11187-11192.
10. Gunasekaran K, et al. (2010) Enhancing antibody Fc heterodimer formation through electrostatic steering effects: Applications to bispecific molecules and monovalent IgG. J Biol Chem 285(25):19637-19646.
11. Davis JH, et al. (2010) SEEDbodies: Fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies. Protein Eng Des Sel 23(4): 195-202.
12. Wu C, et al. (2007) Simultaneous targeting of multiple disease mediators by a dualvariable-domain immunoglobulin. Nat Biotechnol 25(11):1290-1297.
13. Baeuerle PA, Reinhardt C (2009) Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res 69(12):4941-4944.
14. Dimasi N, et al. (2009) The design and characterization of oligospecific antibodies for simultaneous targeting of multiple disease mediators. J Mol Biol 393(3):672-692.
15. Dong J, et al. (2011) A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity. MAbs 3(3):273-288.
16. Mabry R, et al. (2010) Engineering of stable bispecific antibodies targeting IL-17A and IL-23. Protein Eng Des Sel 23(3):115-127.
17. De Bernardis F, et al. (2007) Human domain antibodies against virulence traits of Candida albicans inhibit fungus adherence to vaginal epithelium and protect against experimental vaginal candidiasis. J Infect Dis 195(1):149-157.
18. Shen J, et al. (2007) Single variable domain antibody as a versatile building block for the construction of IgG-like bispecific antibodies. J Immunol Methods 318(1-2):65-74.
19. van der Neut Kolfschoten M, et al. (2007) Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 317(5844):1554-1557.
20. Labrijn AF, et al. (2009) Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nat Biotechnol 27(8):767-771.
21. Labrijn AF, et al. (2011) Species-specific determinants in the IgG CH3 domain enable Fab-arm exchange by affecting the noncovalent CH3-CH3 interaction strength. J Immunol 187(6):3238-3246.
22. Bloom JW, Madanat MS, Marriott D, Wong T, Chan SY (1997) Intrachain disulfide bond in the core hinge region of human IgG4. Protein Sci 6(2):407-415.
23. Rispens T, Ooijevaar-de Heer P, Bende O, Aalberse RC (2011) Mechanism of immunoglobulin G4 Fab-arm exchange. J Am Chem Soc 133(26):10302-10311.
24. Rose RJ, et al. (2011) Quantitative analysis of the interaction strength and dynamics of human IgG4 half molecules by native mass spectrometry. Structure 19(9):1274-1282.
25. Warncke M, et al. (2012) Different adaptations of IgG effector function in human and nonhuman primates and implications for therapeutic antibody treatment. J Immunol 188(9):4405-4411.
26. Bleeker WK, et al. (2004) Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy. J Immunol 173(7):4699- 4707.
27. Teeling JL, et al. (2004) Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 104(6): 1793-1800.
28. Idusogie EE, et al. (2000) Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J Immunol 164(8):4178-4184.
29. Shields RL, et al. (2001) High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 276(9):6591-6604.
30. Hurvitz SA, Hu Y, O'Brien N, Finn RS (2013) Current approaches and future directions in the treatment of HER2-positive breast cancer. Cancer Treat Rev 39(3):219-229.
31. Adams CW, et al. (2006) Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother 55(6):717-727.
32. Slamon DJ, et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11): 783-792.
33. Lewis Phillips GD, et al. (2008) Targeting HER2-positive breast cancer with trastuzumab- DM1, an antibody-cytotoxic drug conjugate. Cancer Res 68(22):9280-9290.
34. Davol PA, Smith JA, Kouttab N, Elfenbein GJ, Lum LG (2004) Anti-CD3 x anti-HER2 bispecific antibody effectively redirects armed T cells to inhibit tumor development and growth in hormone-refractory prostate cancer-bearing severe combined immunodeficient beige mice. Clin Prostate Cancer 3(2):112-121.
35. Jäger M, Schoberth A, Ruf P, Hess J, Lindhofer H (2009) The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor 2. Cancer Res 69(10):4270-4276.
36. Ben-Kasus T, Schechter B, Lavi S, Yarden Y, Sela M (2009) Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: Relevance of receptor endocytosis. Proc Natl Acad Sci USA 106(9):3294-3299.
37. Friedman LM, et al. (2005) Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: Implications for cancer immunotherapy. Proc Natl Acad Sci USA 102(6):1915-1920.
38. Baselga J, et al.; CLEOPATRA Study Group (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366(2):109-119.
39. Schuurman J, et al. (1999) Normal human immunoglobulin G4 is bispecific: It has two different antigen-combining sites. Immunology 97(4):693-698.
40. Moore GL, et al. (2011) A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens. MAbs 3(6):546-557.
41. Strop P, et al. (2012) Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair. J Mol Biol 420(3):204-219.
42. Wing MG, et al. (1996) Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: Involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells. J Clin Invest 98(12):2819-2826.
43. Nesspor TC, Raju TS, Chin CN, Vafa O, Brezski RJ (2012) Avidity confers FcγR binding and immune effector function to aglycosylated immunoglobulin G1. J Mol Recognit 25(3):147-154.